GlassScriptPhysician profile
Stephen A Tang
NPI 1952668238
$49,744.35
in general payments reported to CMS, 2019-2025
44 companies · $15K in 2025
The $15K reported for 2025 was more than what 85% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,378 · 2020: $1,882 · 2021: $3,648 · 2022: $6,955 · 2023: $7,617 · 2024: $13K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25K · Consulting Fee: $6,749 · Travel and Lodging: $3,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24,817.90 |
| Consulting Fee | $6,748.93 |
| Travel and Lodging | $3,315.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $23,281.15 | 2019-2025 | Carto 3, Thermocool Sf, Pentaray Nav |
| Boston Scientific Corporation | $9,065.08 | 2019-2025 | Farapulse, Lux-Dx Insertable Cardiac Monitor, General - Therapies |
| Medtronic, INC. | $8,623.03 | 2021-2025 | Micra, Affera Mapping System, Selectsecure |
| Medtronic Vascular, INC. | $1,959.02 | 2019-2020 | |
| Abbott Laboratories | $1,623.67 | 2019-2025 | Aveir |
| Impulse Dynamics (USA) INC. | $652.60 | 2024-2025 | Optimizer |
| Novartis Pharmaceuticals Corporation | $595.13 | 2023-2025 | |
| Atricure, INC. | $512.96 | 2021-2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| Cardiva Medical, INC. | $506.91 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Amgen INC. | $380.92 | 2023-2025 | Repatha, Repatha |
| Medical Device Business Services, INC. | $340.93 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.78 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $179.34 | 2021-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $176.95 | 2024-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $160.69 | 2023-2025 | Amvuttra |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.